NEW YORK, Feb. 21, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty
and other violations of law by the Board of Directors of Immune
Design Corp. ("IMDZ" or the "Company") (NASDAQ: IMDZ) in connection
with the proposed acquisition of the Company by Merck & Co.,
Inc. ("MRK"). Under the terms of the acquisition agreement,
shareholders will receive $5.85 in
cash for each IMDZ share they own.
If you own IMDZ shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, please contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Visit our website
http://www.weisslawllp.com/immune-design-corp/
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether IMDZ's Board acted to maximize
shareholder value prior to entering into the
agreement. Notably, at least one analyst set a target price of
$9.00 per IMDZ share.
Moreover, IMDZ recently announced promising results for the
Phase 2 clinical trial of its G100 candidate. It reported an
overall response rate of 46% in patients receiving a regimen that
included the G100 candidate and low dose radiation, with patient
responses appearing to be durable. MRK is hoping to capitalize on
the Company's "unique portfolio of approaches to cancer
immunization and adjuvant systems" to strengthen its own portfolio
and improve its vaccine development.
Given these facts, WeissLaw is concentrating its investigation
on whether IMDZ's Board conducted a fair process in agreeing to the
proposed acquisition, whether the proposed acquisition undervalues
the Company, and whether all material information related to the
proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
clients and obtained important corporate governance relief in many
of these cases. If you have information or would like legal
advice concerning possible corporate wrongdoing (including insider
trading, waste of corporate assets, accounting fraud, or materially
misleading information), consumer fraud (including false
advertising, defective products, or other deceptive business
practices), or anti-trust violations, please email us at
stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-immune-design-corp-300799909.html
SOURCE WeissLaw LLP